Treating psoriasis with etanercept in Italian clinical practice: Prescribing practices and duration of remission following discontinuation

Annalisa Arcese, Nicola Aste, Alberta Bettacchi, Germana Camplone, Franca Cantoresi, Marzia Caproni, Domenico Damico, Paolo Fabbri, Giorgio Filosa, Antonia Galluccio, Katharina Hansel, Paolo Lisi, Giuseppe Micali, Maria Letizia Musumeci, Massimiliano Nicolini, Aurora Parodi, Mario Patania, Michele Pezza, Concetta Potenza, Antonio RichettaMarco Simonacci, Piergiusto Trevisan, Giancarlo Valenti, Stefano Calvieri

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Conventional antipsoriatic therapies are often administered until remission, with treatment resumed in the case of relapse, in order to reduce the likelihood of cumulative, dose-dependent toxicities. Biological agents have been safely used in continuous therapy. Objective: To assess the use of etanercept for psoriasis in clinical practice in Italy. Methods: This was an observational study carried out in 13 dermatological centres across Italy in patients with plaque psoriasis (with a Psoriasis Area and Severity Index [PASI] score ≥10) treated with etanercept. The study comprised a treatment and subsequent discontinuation period. Patients were eligible if they had plaque psoriasis and had begun treatment with etanercept between 1 September 2007 and 1 April 2008. Patients were evaluable for the duration of discontinuation analysis if they achieved a PASI reduction ≥50% (PASI50) and a PASI score

Original languageEnglish
Pages (from-to)507-516
Number of pages10
JournalClinical Drug Investigation
Volume30
Issue number8
DOIs
Publication statusPublished - 2010

Fingerprint

Psoriasis
Italy
Therapeutics
Biological Factors
Observational Studies
Etanercept
Recurrence

Keywords

  • Etanercept, therapeutic use
  • Psoriasis, treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Treating psoriasis with etanercept in Italian clinical practice : Prescribing practices and duration of remission following discontinuation. / Arcese, Annalisa; Aste, Nicola; Bettacchi, Alberta; Camplone, Germana; Cantoresi, Franca; Caproni, Marzia; Damico, Domenico; Fabbri, Paolo; Filosa, Giorgio; Galluccio, Antonia; Hansel, Katharina; Lisi, Paolo; Micali, Giuseppe; Musumeci, Maria Letizia; Nicolini, Massimiliano; Parodi, Aurora; Patania, Mario; Pezza, Michele; Potenza, Concetta; Richetta, Antonio; Simonacci, Marco; Trevisan, Piergiusto; Valenti, Giancarlo; Calvieri, Stefano.

In: Clinical Drug Investigation, Vol. 30, No. 8, 2010, p. 507-516.

Research output: Contribution to journalArticle

Arcese, A, Aste, N, Bettacchi, A, Camplone, G, Cantoresi, F, Caproni, M, Damico, D, Fabbri, P, Filosa, G, Galluccio, A, Hansel, K, Lisi, P, Micali, G, Musumeci, ML, Nicolini, M, Parodi, A, Patania, M, Pezza, M, Potenza, C, Richetta, A, Simonacci, M, Trevisan, P, Valenti, G & Calvieri, S 2010, 'Treating psoriasis with etanercept in Italian clinical practice: Prescribing practices and duration of remission following discontinuation', Clinical Drug Investigation, vol. 30, no. 8, pp. 507-516. https://doi.org/10.2165/11537470-000000000-00000
Arcese, Annalisa ; Aste, Nicola ; Bettacchi, Alberta ; Camplone, Germana ; Cantoresi, Franca ; Caproni, Marzia ; Damico, Domenico ; Fabbri, Paolo ; Filosa, Giorgio ; Galluccio, Antonia ; Hansel, Katharina ; Lisi, Paolo ; Micali, Giuseppe ; Musumeci, Maria Letizia ; Nicolini, Massimiliano ; Parodi, Aurora ; Patania, Mario ; Pezza, Michele ; Potenza, Concetta ; Richetta, Antonio ; Simonacci, Marco ; Trevisan, Piergiusto ; Valenti, Giancarlo ; Calvieri, Stefano. / Treating psoriasis with etanercept in Italian clinical practice : Prescribing practices and duration of remission following discontinuation. In: Clinical Drug Investigation. 2010 ; Vol. 30, No. 8. pp. 507-516.
@article{d42b440494254057b92cc307d386434a,
title = "Treating psoriasis with etanercept in Italian clinical practice: Prescribing practices and duration of remission following discontinuation",
abstract = "Background: Conventional antipsoriatic therapies are often administered until remission, with treatment resumed in the case of relapse, in order to reduce the likelihood of cumulative, dose-dependent toxicities. Biological agents have been safely used in continuous therapy. Objective: To assess the use of etanercept for psoriasis in clinical practice in Italy. Methods: This was an observational study carried out in 13 dermatological centres across Italy in patients with plaque psoriasis (with a Psoriasis Area and Severity Index [PASI] score ≥10) treated with etanercept. The study comprised a treatment and subsequent discontinuation period. Patients were eligible if they had plaque psoriasis and had begun treatment with etanercept between 1 September 2007 and 1 April 2008. Patients were evaluable for the duration of discontinuation analysis if they achieved a PASI reduction ≥50{\%} (PASI50) and a PASI score",
keywords = "Etanercept, therapeutic use, Psoriasis, treatment",
author = "Annalisa Arcese and Nicola Aste and Alberta Bettacchi and Germana Camplone and Franca Cantoresi and Marzia Caproni and Domenico Damico and Paolo Fabbri and Giorgio Filosa and Antonia Galluccio and Katharina Hansel and Paolo Lisi and Giuseppe Micali and Musumeci, {Maria Letizia} and Massimiliano Nicolini and Aurora Parodi and Mario Patania and Michele Pezza and Concetta Potenza and Antonio Richetta and Marco Simonacci and Piergiusto Trevisan and Giancarlo Valenti and Stefano Calvieri",
year = "2010",
doi = "10.2165/11537470-000000000-00000",
language = "English",
volume = "30",
pages = "507--516",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "8",

}

TY - JOUR

T1 - Treating psoriasis with etanercept in Italian clinical practice

T2 - Prescribing practices and duration of remission following discontinuation

AU - Arcese, Annalisa

AU - Aste, Nicola

AU - Bettacchi, Alberta

AU - Camplone, Germana

AU - Cantoresi, Franca

AU - Caproni, Marzia

AU - Damico, Domenico

AU - Fabbri, Paolo

AU - Filosa, Giorgio

AU - Galluccio, Antonia

AU - Hansel, Katharina

AU - Lisi, Paolo

AU - Micali, Giuseppe

AU - Musumeci, Maria Letizia

AU - Nicolini, Massimiliano

AU - Parodi, Aurora

AU - Patania, Mario

AU - Pezza, Michele

AU - Potenza, Concetta

AU - Richetta, Antonio

AU - Simonacci, Marco

AU - Trevisan, Piergiusto

AU - Valenti, Giancarlo

AU - Calvieri, Stefano

PY - 2010

Y1 - 2010

N2 - Background: Conventional antipsoriatic therapies are often administered until remission, with treatment resumed in the case of relapse, in order to reduce the likelihood of cumulative, dose-dependent toxicities. Biological agents have been safely used in continuous therapy. Objective: To assess the use of etanercept for psoriasis in clinical practice in Italy. Methods: This was an observational study carried out in 13 dermatological centres across Italy in patients with plaque psoriasis (with a Psoriasis Area and Severity Index [PASI] score ≥10) treated with etanercept. The study comprised a treatment and subsequent discontinuation period. Patients were eligible if they had plaque psoriasis and had begun treatment with etanercept between 1 September 2007 and 1 April 2008. Patients were evaluable for the duration of discontinuation analysis if they achieved a PASI reduction ≥50% (PASI50) and a PASI score

AB - Background: Conventional antipsoriatic therapies are often administered until remission, with treatment resumed in the case of relapse, in order to reduce the likelihood of cumulative, dose-dependent toxicities. Biological agents have been safely used in continuous therapy. Objective: To assess the use of etanercept for psoriasis in clinical practice in Italy. Methods: This was an observational study carried out in 13 dermatological centres across Italy in patients with plaque psoriasis (with a Psoriasis Area and Severity Index [PASI] score ≥10) treated with etanercept. The study comprised a treatment and subsequent discontinuation period. Patients were eligible if they had plaque psoriasis and had begun treatment with etanercept between 1 September 2007 and 1 April 2008. Patients were evaluable for the duration of discontinuation analysis if they achieved a PASI reduction ≥50% (PASI50) and a PASI score

KW - Etanercept, therapeutic use

KW - Psoriasis, treatment

UR - http://www.scopus.com/inward/record.url?scp=77954198236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954198236&partnerID=8YFLogxK

U2 - 10.2165/11537470-000000000-00000

DO - 10.2165/11537470-000000000-00000

M3 - Article

C2 - 20586516

AN - SCOPUS:77954198236

VL - 30

SP - 507

EP - 516

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 8

ER -